DE69940264D1 - Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 - Google Patents

Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1

Info

Publication number
DE69940264D1
DE69940264D1 DE69940264T DE69940264T DE69940264D1 DE 69940264 D1 DE69940264 D1 DE 69940264D1 DE 69940264 T DE69940264 T DE 69940264T DE 69940264 T DE69940264 T DE 69940264T DE 69940264 D1 DE69940264 D1 DE 69940264D1
Authority
DE
Germany
Prior art keywords
geneva
product
cancer antigen
tumor suppressive
suppressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940264T
Other languages
English (en)
Inventor
Haruo Sugiyama
Yoshihiro Oka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16714530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69940264(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by International Institute of Cancer Immunology Inc filed Critical International Institute of Cancer Immunology Inc
Application granted granted Critical
Publication of DE69940264D1 publication Critical patent/DE69940264D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69940264T 1998-07-31 1999-07-30 Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1 Expired - Lifetime DE69940264D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21809398 1998-07-31
PCT/JP1999/004130 WO2000006602A1 (fr) 1998-07-31 1999-07-30 Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1

Publications (1)

Publication Number Publication Date
DE69940264D1 true DE69940264D1 (de) 2009-02-26

Family

ID=16714530

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940264T Expired - Lifetime DE69940264D1 (de) 1998-07-31 1999-07-30 Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1

Country Status (15)

Country Link
US (7) US7030212B1 (de)
EP (3) EP2280031B1 (de)
JP (2) JP4422903B2 (de)
KR (1) KR100767554B1 (de)
CN (4) CN1560078B (de)
AT (1) ATE420112T1 (de)
AU (1) AU4932199A (de)
BR (1) BRPI9912663B8 (de)
CA (1) CA2337743C (de)
DE (1) DE69940264D1 (de)
DK (1) DK1103564T3 (de)
ES (1) ES2318898T3 (de)
HK (4) HK1036073A1 (de)
PT (1) PT1103564E (de)
WO (1) WO2000006602A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1394497A (en) 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
DK1103564T3 (da) 1998-07-31 2009-05-11 Int Inst Cancer Immunology Inc Cancerantigener baseret på tumorsuppressorgen WT1-produkt
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
ES2310052T3 (es) * 1998-09-30 2008-12-16 Corixa Corporation Composiciones y metodos para la inmunoterapia especifica de wt1.
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
JP3728439B2 (ja) * 2001-03-22 2005-12-21 治夫 杉山 Ｗｔ１改変ペプチド
CN1320923C (zh) * 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028757A1 (fr) 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
CN100408683C (zh) 2002-06-12 2008-08-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
US7378384B2 (en) 2002-09-20 2008-05-27 International Institute Of Cancer Immunology, Inc. WT1 substitution peptides
KR101399678B1 (ko) 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
CA2893995A1 (en) 2003-06-27 2005-01-06 International Institute Of Cancer Immunology, Inc. Method of diagnosis of cancer
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
PL1731605T3 (pl) * 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1
ES2531142T3 (es) 2005-10-17 2015-03-11 Sloan Kettering Inst Cancer Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
BRPI0619255B8 (pt) * 2005-11-30 2021-05-25 Chugai Seiyaku Kabishiki Kaisha composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
JP5239041B2 (ja) 2007-02-07 2013-07-17 一般財団法人阪大微生物病研究会 癌の治療剤
DK2119778T3 (en) 2007-02-27 2016-01-25 Int Inst Cancer Immunology Inc A process for the activation of the helper T cell, and composition for use in this process
AU2008222061B2 (en) 2007-03-05 2014-03-20 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
EP3384926A1 (de) * 2007-12-05 2018-10-10 International Institute of Cancer Immunology, Inc. Krebsimpfstoffzusammensetzung
AU2011313327B2 (en) 2010-10-05 2015-10-22 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
CA2839663A1 (en) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
EP2776451B1 (de) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-gezielte t-zellen-immuntherapie gegen krebs
EP2792745B1 (de) 2011-12-14 2017-11-15 National University Corporation Kochi University Modifizierung eines helfer-t-zellen-induzierenden polypeptids
EP2802347B1 (de) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogene wt-1-peptide und verfahren zur verwendung davon
WO2014007266A1 (ja) 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
TWI646970B (zh) 2012-12-17 2019-01-11 大塚製藥股份有限公司 活化輔助ｔ細胞的方法
US9919037B2 (en) 2013-01-15 2018-03-20 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP2014169280A (ja) 2013-02-05 2014-09-18 Nitto Denko Corp 経皮または粘膜投与用ワクチン組成物
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
IN2014CH00391A (de) * 2013-02-05 2015-04-03 Nitto Denko Corp
US20140234377A1 (en) 2013-02-05 2014-08-21 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2762152A1 (de) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1-Peptidkrebsimpfstoffzusammensetzung zur transdermalen Verabreichung
CA2840988A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
IN2014CH00393A (de) * 2013-02-05 2015-04-03 Nitto Denko Corp
EP2762154A3 (de) 2013-02-05 2015-01-21 Nitto Denko Corporation Impfstoff zur transdermalen Verabreichung
JP6294868B2 (ja) * 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
DK2982681T3 (en) * 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
EP3199175B1 (de) 2014-09-27 2022-03-23 Sumitomo Dainippon Pharma Co., Ltd. Pharmazeutische zusammensetzung zur injektion
AU2016320877A1 (en) * 2015-09-10 2018-04-19 Memorial Sloan Kettering Cancer Center Methods of treating multiple myeloma and plasma cell leukemia by T cell therapy
US11033613B2 (en) 2015-11-20 2021-06-15 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer
CN109069599A (zh) * 2016-03-03 2018-12-21 法国古士塔柏罗斯学院 针对癌症的基于ptp的疫苗
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
EP3604325A4 (de) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. Wt1-krebs-antigen-peptid und peptid-konjugat-körper damit
CA3113212A1 (en) 2018-09-28 2020-04-02 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
WO2020071551A1 (ja) * 2018-10-05 2020-04-09 株式会社癌免疫研究所 良性腫瘍の予防または治療薬
TW202045528A (zh) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
US20220409661A1 (en) 2019-08-20 2022-12-29 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
JP2023508726A (ja) 2019-12-31 2023-03-03 エリクサージェン セラピューティクス，インコーポレイティド 細胞及び組織への核酸及びタンパク質の温度ベースの一過性送達
US20230183316A1 (en) 2020-05-12 2023-06-15 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
JP2023526723A (ja) * 2020-05-12 2023-06-23 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
EP4385519A1 (de) 2021-08-12 2024-06-19 International Institute of Cancer Immunology, Inc. Pharmazeutische zusammensetzung und verfahren zur behandlung oder prävention von krebs

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
JP2546254B2 (ja) 1987-02-23 1996-10-23 澁谷工業株式会社 ガス詰め充填装置
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
WO1991007509A1 (en) 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
CA2069541C (en) * 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
CA2178902A1 (en) 1993-12-14 1995-06-22 Drew Pardoll Controlled release of pharmaceutically active substances for immunotherapy
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
EP1167379A3 (de) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatorische Oligonukleotide
JP3904260B2 (ja) * 1995-06-01 2007-04-11 岸本 忠三 ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
AU5779696A (en) 1995-06-01 1996-12-18 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonuc leotide derivative against wilms' tumor gene (wt1)
CA2231774C (en) 1995-09-19 2010-09-07 Jens Kossmann Plants which synthesize a modified starch, process for the production thereof and modified starch
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
AU1394497A (en) 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
DK1103564T3 (da) * 1998-07-31 2009-05-11 Int Inst Cancer Immunology Inc Cancerantigener baseret på tumorsuppressorgen WT1-produkt
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
ES2310052T3 (es) * 1998-09-30 2008-12-16 Corixa Corporation Composiciones y metodos para la inmunoterapia especifica de wt1.
US20030215458A1 (en) 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
CZ20012544A3 (cs) 1999-01-12 2002-01-16 Smithkline Beecham Biologicals S.A. Farmaceutické balení
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
CA2313392A1 (en) 1999-07-22 2001-01-22 Sumitomo Pharmaceuticals Company, Limited Agent for induction of antigen-specific t cell
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
JP3728439B2 (ja) 2001-03-22 2005-12-21 治夫 杉山 Ｗｔ１改変ペプチド
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003028757A1 (fr) 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
CN100408683C (zh) 2002-06-12 2008-08-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
AU2003262094A1 (en) * 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
US7378384B2 (en) * 2002-09-20 2008-05-27 International Institute Of Cancer Immunology, Inc. WT1 substitution peptides
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
CA2893995A1 (en) * 2003-06-27 2005-01-06 International Institute Of Cancer Immunology, Inc. Method of diagnosis of cancer
CN101580538B (zh) 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
PL1731605T3 (pl) 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1

Also Published As

Publication number Publication date
CN1178956C (zh) 2004-12-08
CA2337743A1 (en) 2000-02-10
PT1103564E (pt) 2009-03-13
US20160243209A1 (en) 2016-08-25
EP1103564B1 (de) 2009-01-07
JP2010059172A (ja) 2010-03-18
AU4932199A (en) 2000-02-21
CN100560130C (zh) 2009-11-18
BRPI9912663B8 (pt) 2021-07-06
KR100767554B1 (ko) 2007-10-17
US7517950B2 (en) 2009-04-14
EP2048160B1 (de) 2015-01-07
CN1560078B (zh) 2011-06-22
ATE420112T1 (de) 2009-01-15
EP2280031B1 (de) 2015-04-15
US7807792B2 (en) 2010-10-05
US9403886B2 (en) 2016-08-02
JP4422903B2 (ja) 2010-03-03
US7030212B1 (en) 2006-04-18
CN102198266A (zh) 2011-09-28
US20060093615A1 (en) 2006-05-04
US20050266014A1 (en) 2005-12-01
HK1036073A1 (en) 2001-12-21
BRPI9912663A (pt) 2001-05-02
US20090281043A1 (en) 2009-11-12
KR20010072112A (ko) 2001-07-31
EP2048160A1 (de) 2009-04-15
CN1314916A (zh) 2001-09-26
US7608685B1 (en) 2009-10-27
HK1153761A1 (en) 2012-04-05
EP1103564A1 (de) 2001-05-30
WO2000006602A1 (fr) 2000-02-10
EP1103564A4 (de) 2005-02-02
HK1130069A1 (en) 2009-12-18
EP2280031A1 (de) 2011-02-02
HK1038929A1 (en) 2002-04-04
US7390871B2 (en) 2008-06-24
CN1762490A (zh) 2006-04-26
HK1038929B (zh) 2005-05-06
US20090143291A1 (en) 2009-06-04
CN1560078A (zh) 2005-01-05
DK1103564T3 (da) 2009-05-11
ES2318898T3 (es) 2009-05-01
BRPI9912663B1 (pt) 2011-05-31
CA2337743C (en) 2015-07-07
JP5230579B2 (ja) 2013-07-10

Similar Documents

Publication Publication Date Title
DE69940264D1 (de) Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
CY1113185T1 (el) Μεθοδοι συνενωσης αποδεκτη πεπτιδιου
UA84284C2 (ru) Способы лечения, профилактики и диагностики инфекции helicobacter cerdo
MA23778A1 (fr) Purine-6-ones-2,9 disubstituees
DK0817851T3 (da) DNA, der koder for humant papillomvirus type 18
ZA975588B (en) Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
FI970071A0 (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä
NL193944B (nl) Onkruidbestrijdingsmiddelen op basis van 2- 1-(3-chloorallyloxyamino)-alkylideen -5-alkylthioalkyl-1,3-cyclohexaandion.
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
PT1005532E (pt) Moleculas de acido nucleico isoladas que codificam para membros da familia ssx e suas utilizacoes
FI890857A0 (fi) Skaopenhet att placeras under arbetsbord, i synnerhet diskbord, i ett koek.
ID27733A (id) Metoksiminofenilasetamida
BR0103900A (pt) Processos para a preparação de piranos substituìdos
IT1277414B1 (it) Uso di macromolecole di tipo dendrimerico come catalizzatori o coadiuvanti delle reazioni in condizioni di trasferimento di fase
ITVI940084A0 (it) Impilatore per prodotti laminari flessibili, particolarmente per pellied affini.
RU98108898A (ru) Штамм "внивип-деп" для получения вакцины против реовирусного теносиновита кур
Na et al. Similarity analyses of partial differential equations by the multiparameter Lie group: technical report
IT1256078B (it) Ligandi kit solubili
CY1112454T1 (el) Ανασυνδυασμενη καρβοξυπεπτιδαση β
IT1293257B1 (it) Apparato ortodontico di trazione extra orale, di tipo composito.
RU2002103767A (ru) Штамм "Вл-94" парвовируса свиней для изготовления вакцинных препаратов
RU95114754A (ru) Продукты олигомеризации 10-пропенилфенотиазина в качестве стабилизаторов полиолефинов
DK73991D0 (da) Toerreanlaeg for biologiske emner, f.eks. geler eller lignende
IT208301Z2 (it) Carrello espositore, particolarmente per attrezzi da giardinaggio.
IT8722938A0 (it) Carrello scorrevole per vetrine, esimili.

Legal Events

Date Code Title Description
8363 Opposition against the patent